Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Ozempic and Wegovy might be making it harder for physicians to guide patients toward lifestyle changes − the real key to long ...
A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk’s Wegovy. Eli ...
The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
As the Biden administration is proposing drugs like Ozempic and Wegovy be covered by Medicare and Medicaid, Black people need ...
Doctors say early obesity intervention can help prevent later health problems. But prescribing GLP-1s, such as Ozempic and ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
The dosage of semaglutide in Wegovy is higher than in Ozempic, which is why Wegovy tends to lead to greater weight loss results​​. For those focused purely on weight loss, Wegovy may offer more ...